18 tracked 13F filers disclose a position in QNRX as of the latest SEC 13F filings, a combined $4.9M in reported value. Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| # | Fund | Position value | Shares | Last move | As of | History |
|---|---|---|---|---|---|---|
| 1 | Ikarian Capital, LLC | $1.4M | 212K | —Held | Q1 2026 | |
| 2 | Woodline Partners LP | $525K | 80K | —Held | Q1 2026 | |
| 3 | MILLENNIUM MANAGEMENT LLC | $503K | 76K | ▲+1.9% Added · +1K sh | Q1 2026 | |
| 4 | Aberdeen Group plc | $495K | 75K | —Held | Q1 2026 | |
| 5 | Soleus Capital Management, L.P. | $352K | 73K | —Held | Q2 2026 | |
| 6 | AIGH Capital Management LLC | $339K | 70K | ▲+37% Added · +19K sh | Q2 2026 | |
| 7 | Centiva Capital, LP | $396K | 60K | ▲+398% Added · +48K sh | Q1 2026 | |
| 8 | BOOTHBAY FUND MANAGEMENT, LLC | $395K | 60K | —Held | Q1 2026 | |
| 9 | CITADEL ADVISORS LLC | $215K | 33K | ▲New +33K sh | Q1 2026 | |
| 10 | Velan Capital Investment Management LP | $157K | 32K | ▼−62% Reduced · −52K sh | Q2 2026 | |
| 11 | Birchview Capital, LP | $97K | 20K | —Held | Q2 2026 | |
| 12 | MORGAN STANLEY | $26K | 4K | ▲+33% Added · +1K sh | Q1 2026 | |
| 13 | UBS Group AG | $17K | 3K | ▲148× Added · +2K sh | Q1 2026 | |
| 14 | RHUMBLINE ADVISERS | $10K | 2K | ▼−8.7% Reduced · −145 sh | Q1 2026 | |
| 15 | BARCLAYS PLC | $9K | 1K | ▲New +1K sh | Q1 2026 | |
| 16 | GAMMA Investing LLC | $2K | 439 | ▼−74% Reduced · −1K sh | Q2 2026 | |
| 17 | SBI Securities Co., Ltd. | $2K | 355 | ▲178× Added · +353 sh | Q2 2026 | |
| 18 | ROYAL BANK OF CANADA | $0 | 11 | ▲New +11 sh | Q1 2026 |
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
Last quarter, 1 fund opened a new position in QNRX and 3 added to an existing one, while 2 reduced and 0 exited entirely — based on 13F filings from active, signal-eligible managers (passive index funds and other mechanical holders are excluded from this count).
| Company | Co-held by | Combined value |
|---|---|---|
| XENON PHARMACEUTICALS INCXENE | 9 funds | $243.4M |
| PRAXIS PRECISION MEDICINES IPRAX | 9 funds | $242.0M |
| CYTOKINETICS INCCYTK | 9 funds | $204.5M |
| ULTRAGENYX PHARMACEUTICAL INRARE | 9 funds | $100.3M |
| LEGEND BIOTECH CORP-ADRLEGN | 9 funds | $58.9M |
| SOLID BIOSCIENCES INCSLDB | 9 funds | $33.4M |
| SANDISK CORPSNDK | 8 funds | $1.5B |
| MERCK & CO. INC.MRK | 8 funds | $1.4B |
| ELI LILLY & COLLY | 8 funds | $1.4B |
| UNITEDHEALTH GROUP INCUNH | 8 funds | $1.1B |
| FREEPORT-MCMORAN INCFCX | 8 funds | $1.1B |
| LAM RESEARCH CORPLRCX | 8 funds | $871.6M |
Ranked by how many of QNRX's institutional holders also hold each name, a cross-fund conviction signal.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| Oct 14, 2025 | LANGER DENNIS | Director | Buy (P) | 15K | $129K |
| Dec 23, 2024 | Culverwell Anthony James | Director | Buy (P) | 100K | $45K |
| Dec 23, 2024 | Dunn Gordon | Chief Financial Officer | Buy (P) | 122K | $55K |
| Dec 23, 2024 | Myers Michael | Chief Executive Officer, Director | Buy (P) | 556K | $250K |
| Dec 23, 2024 | Carter Denise P. | Chief Operating Officer, Director | Buy (P) | 556K | $250K |
| Sep 10, 2024 | Dunn Gordon | Chief Financial Officer | Buy (P) | 10K | $9K |
| Sep 10, 2024 | Dunn Gordon | Chief Financial Officer | Buy (P) | 10K | $7K |
| Sep 9, 2024 | Dunn Gordon | Chief Financial Officer | Buy (P) | 4K | $3K |
| Sep 9, 2024 | Dunn Gordon | Chief Financial Officer | Buy (P) | 4K | $3K |
| Sep 9, 2024 | Dunn Gordon | Chief Financial Officer | Buy (P) | 856 | $685 |
| Sep 4, 2024 | Myers Michael | Chief Executive Officer, Director | Buy (P) | 5K | $4K |
| Sep 4, 2024 | Myers Michael | Chief Executive Officer, Director | Buy (P) | 24K | $19K |
Connected entities for QNRX
This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/QNRX/capital-change-brief"
Use Arkolith's capital_change_brief for QNRX. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
13F holdings + Form 4 insider transactions + end-of-day price history + the live filing stream, joined for QNRX. Filings are public domain, sourced to SEC EDGAR; price series derived from end-of-day closes.